Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081518 · ClinicalTrials.gov registry record · Phase 1
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05081518 is a Phase 1 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 1 participants.
The verdict
NCT05081518, a Phase 1 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.
Interventions
- DRUG Placebo
- DRUG Lu AG06466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05081518
The ClinicalTrials.gov registry entry for NCT05081518 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05081518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05081518 about?
NCT05081518 is a clinical study titled "A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy". The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.
What is the current status of trial NCT05081518?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-09-29. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT05081518?
The interventions under investigation include: Placebo (DRUG), Lu AG06466 (DRUG).
Who is sponsoring clinical trial NCT05081518?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.